CSTL — Castle Biosciences, Inc. stock price, charts and financials

QT69Castle Biosciences, Inc.

Castle Biosciences, Inc. (NASDAQ: CSTL) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
30.39
+2.39+8.54%
OverviewShort InterestFilings
CSTLQT69Castle Biosciences, Inc.·NASDAQ
30.39+8.54%
TA
Loading chart...
Signal & projected range
Earnings big beat — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
PSNL+4.27%$13.20FLGT+6.40%$17.61CDNA+9.47%$47.85PRE-0.64%$18.52NEOG-1.16%$11.90MYGN+5.59%$3.02VCYT-3.17%$44.85RDNT+4.74%$66.80
Snapshot
Index-P/E-EPS (ttm)-0.44Insider Own2.48%Shs Outstand30.33MPerf Week13.41%
Market Cap849.24MForward P/E-EPS next Y-0.96Insider Trans-27.78%Shs Float26.99MPerf Month13.31%
Enterprise Value823.77MPEG0.42EPS next Q-Inst Own94.13%Short Float5.27%Perf Quarter14.33%
Income-19.36MP/S2.38EPS this Y-235.68%Inst Trans-Short Ratio3.63Perf Half Y-28.50%
Sales357.28MP/B1.81EPS next Y35.22%ROA-3.46%Short Interest1.42MPerf YTD-28.02%
Book/sh-P/C19.96EPS next 5Y-ROE-4.15%52W High48.06 -36.77%Perf Year74.13%
Cash/sh-P/FCF41.19EPS past 3/5Y-ROIC-5.70%52W Low15.84 91.91%Perf 3Y80.53%
Dividend Est.-EV/EBITDA-Sales past 3/5Y35.92% 40.42%Gross Margin54.13%Volatility7.79% 5.11%Perf 5Y-59.30%
Dividend TTM-EV/Sales2.31EPS Y/Y TTM-170.97%Oper. Margin-8.13%ATR (14)1.40Perf 10Y-
Dividend Ex-Date-Quick Ratio5.85Sales Y/Y TTM2.41%Profit Margin-5.43%RSI (14)71.40Recom2.00
Dividend Gr. 3/5Y-Current Ratio6.04EPS Q/Q-145.00%SMA2014.42%Beta1.00Target Price37.75
Payout0.00%Debt/Eq0.08Sales Q/Q-4.55%SMA5023.53%Rel Volume4.09Prev Close28.00
Employees883LT Debt/Eq0.08EarningsNov 02SMA200-3.00%Avg Volume430.20KPrice30.39
IPO DateJul 25, 2019Option/ShortYes / YesEPS/Sales Surpr.0.00% 6.31%Net Debt/EBITDA6.34Volume1,757,829Change8.54%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-31-26ReiteratedRobert W. Baird$43 → $36
Jun-24-26InitiatedRoth CapitalBuy$40
May-29-26ReiteratedKeyBancOverweight$50 → $35
Apr-20-26ReiteratedCanaccord GenuityBuy$50 → $40
Jan-29-26ReiteratedKeyBancOverweight$36 → $50
Jan-26-26ReiteratedGuggenheimBuy$43 → $47
Jan-12-26ReiteratedLake StreetBuy$52
Jan-05-26ReiteratedGuggenheimBuy$30 → $43
Dec-22-25ReiteratedCanaccord GenuityBuy$42 → $50
Dec-12-25ReiteratedBTIGBuy$45 → $50
Latest News
Jul-31-26
Jul-31-2603:53AM
Castle Biosciences, Inc. (CSTL) Q2 2026 Earnings Call Transcriptseekingalpha.com
Jul-30-26
Jul-30-2609:04PM
Castle Biosciences (NASDAQ:CSTL) Surges After Smashing Q2 Estimates and Raising GuidanceChartMill
07:00PM
Castle Biosciences, Inc. (CSTL) Reports Q2 Loss, Tops Revenue Estimateszacks.com
06:06PM
Castle Biosciences Q2 Earnings Call Highlightsmarketbeat.com
Jul-22-26
Jul-22-2607:00AM
Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conferenceprnewswire.com
Jul-14-26
Jul-14-2604:30PM
Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Testprnewswire.com
Jul-09-26
Jul-09-2607:00AM
Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026prnewswire.com
Jun-25-26
Jun-25-2604:35PM
Castle Biosciences Announces Published Study In 'Dermatology And Therapy' Showing DecisionDx-Melanoma Test Outperforms MIA Nomogram In Predicting Sentinel Lymph Node Positivity RiskBenzinga
12:21PM
This Keurig Dr Pepper Analyst Turns Bullish; Here Are Top 4 Upgrades For ThursdayBenzinga
10:17AM
This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For ThursdayBenzinga
08:44AM
This Tonix Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga
06:39AM
Roth Capital Initiates Coverage On Castle Biosciences with Buy Rating, Announces Price Target of $40Benzinga
Company

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.

Ownership
Total institutional ownership94.13%

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue35834433222013794635223
Cost of Goods Sold Incl. D&A6071604532161075
Gross Profit19327327217510578534517
Selling, General and Administrative Excl. Other24422920018014387483016
Research and Development5652525445301375
Other Operating Expense3035119-101-100
Operating Income-29-439-68-73-40-77-4
Interest Expense001000352
Unusual Expense
—————————
Non-Operating Income (Expense)913131140-130
Net Income Before Taxes-19-3022-57-69-40-105-6
Income Taxes0-530-2-9000
Consolidated Net Income-20-2418-57-67-31-105-6
Net Income From Continuing Operations-20-2418-57-67-31-105-6
Net Income-20-2418-57-67-31-105-6
EPS (Recurring)-0.66-0.830.66-2.14-2.58-1.24-0.540.35-0.60
EPS (Basic, Before Extraordinaries)-0.66-0.830.66-2.14-2.58-1.24-0.540.35-0.60
EPS (Diluted)-0.66-0.830.62-2.14-2.58-1.24-0.54-0.21-0.60
EBITDA-41138-45-58-37-710-4
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——42.98——————
Price To Sales Ratio2.553.282.252.654.4711.4020.255.95—
Gross Margin53.9179.3681.9379.5576.6482.9884.1386.5473.91
Operating Margin-8.10-12.502.71-30.91-53.28-42.55-11.1113.46-17.39
Net Margin-5.59-6.985.42-25.91-48.91-32.98-15.879.62-26.09
Shares Outstanding30292827262519911
Market Capitalization9121,1287465836121,0721,276309—
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$47.30$38.07$28.84$19.62$10.39● Close Price0.00M0.90M1.79M2.69M3.59MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
MAETZOLD DEREK JPres. & Chief Exec. OfficerJul 27 '26Sale24.169,002217,53111,812Jul 29
MAETZOLD DEREK JPres. & Chief Exec. OfficerJul 27 '26Option Exercise2.396,21414,85127,693Jul 29
MAETZOLD DEREK JPres. & Chief Exec. OfficerJul 14 '26Sale22.923,33876,50712,090Jul 16
MAETZOLD DEREK JPres. & Chief Exec. OfficerJul 14 '26Option Exercise2.395501,31522,029Jul 16
MAETZOLD DEREK JPres. & Chief Exec. OfficerJul 01 '26Sale24.299,002218,65912,368Jul 06
MAETZOLD DEREK JPres. & Chief Exec. OfficerJul 01 '26Option Exercise2.396,21414,85127,693Jul 06
Oelschlager Kristen MChief Operating OfficerJul 01 '26Sale24.428,586209,65021,874Jul 06
Oelschlager Kristen MChief Operating OfficerJun 16 '26Sale20.718,587177,83730,460Jun 18
MAETZOLD DEREK JPres. & Chief Exec. OfficerJun 15 '26Sale20.663,33868,96312,646Jun 17
MAETZOLD DEREK JPres. & Chief Exec. OfficerJun 15 '26Option Exercise2.395501,31522,029Jun 17
Cole G BradleyDirectorMay 22 '26Option Exercise0.0013,667032,976May 27
BRADBURY DANIELDirectorMay 22 '26Option Exercise0.0013,667022,340May 27
Harrison MilesDirectorMay 22 '26Option Exercise0.0013,667035,631May 27
Olson TiffanyDirectorMay 22 '26Option Exercise0.0013,667039,573May 27
Goldberg EllenDirectorMay 22 '26Option Exercise0.0013,667040,921May 27
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.